Navigation Links
DATATRAK International, Inc. Announces Year-End Backlog
Date:1/13/2010

CLEVELAND, Jan. 13 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported its year-end backlog as of December 31, 2009.

At December 31, 2009, backlog was $9,487,000 compared to $8,891,000 at September 30, 2009, a 7% increase. The December 31, 2009 backlog amount of $9,487,000 represents the second consecutive quarter-over-quarter increase in backlog.

"I think our DATATRAK ONE™ vision of a unified technology solution has really taken hold with drug trial sponsors and Contract Research Organizations (CROs) and is evident by the increase in backlog," stated Laurence Birch, Chairman of the Board of DATATRAK International, Inc. "A lot of our competitors market the interoperability of their product offerings, which by definition means the capability of two or more software routines to work harmoniously together. While this might be true, it means extra work, additional cost and ultimately a heightened risk for compromised data. Our clients, unlike our competitors' clients, don't have to worry about interoperability issues such as database reconciliation, stale data vs. real-time data, multiple user names and passwords and undertaking additional validation efforts. Our unified solution has been built entirely on one platform with no required linkage to external systems or scheduled routines."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONE™, which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical™ product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical™ software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

RELATED LINKS
http://www.datatrak.net

'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
2. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
3. DATATRAK International Reports First Quarter Results for 2008
4. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
5. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
6. DATATRAK eClinical(TM) Supports Multifaceted Studies
7. DATATRAK to Present at 2009 SCDM Annual Conference
8. DATATRAK Signs 6 Year Study with New Device Client
9. DATATRAK Signs Five-Year Registry Study
10. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
11. PFC Pharma Joins DATATRAKs CRO Connect Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
(Date:2/5/2016)... 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ), ... services to office-based dental, animal health and medical practitioners, ... to acquire a majority ownership interest in Dental Cremer ... Brazil . ... Cremer is the dental distribution business of Cremer S.A. ...
Breaking Medicine Technology:
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/7/2016)... ... 07, 2016 , ... Women's Excellence staff, in all four locations, wore red ... Red Day is the first Friday each February and a day to bring attention ... 3 deaths among women each year – more than all cancers combined. Go Red ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability ... in design and manufacturing not only reduce the weight of the unit, they ...
(Date:2/5/2016)... Rosa, CA (PRWEB) , ... February 05, 2016 ... ... pleased to announce the addition of micro-needling services in their Napa Valley office. ... The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part ...
Breaking Medicine News(10 mins):